Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Search Results

Refine Your Search

By Sector

Sort by: Date|Relevance

Diagnos increases footprint, and endorsements mount for AI tech that averts illness

Applying Artificial Intelligence (AI) for early detection tests of vascular change in the retina, targeting the diabetes market for vision loss prevention & soon cardiovascular disease. Valuation and Assumptions: Based on due diligence and valuation estimates, Mar...
Fredrick William | June 4, 2020 |

Why is this Company combining Artificial Intelligence and Psychedelics to address Mental Afflictions

(Click image to play video) Did you know that in Canada, it is estimated that by the age of 40, half of the population will have, or will have had, a mental illness? The recent surge of interest in psychedelic drugs is due to their potential for more effective tr...
Dave Jackson | May 10, 2021 |

Psychedelic Leader to Advance Mental Health in 2021 with Growth of Clinics, Lab and Partnerships

(Image via Numinus Wellness Inc.) In 2020, Health Canada began allowing select patients to take psilocybin for relief of end-of-life-distress. This was followed by a proposed regulation revision that could allow doctors to prescribe both psilocybin and MDMA for t...
Stockhouse Editorial | January 14, 2021 |

Buzz on the Bullboards: The calm before another September rally?

It’s the last leg of what looks like an end-of-month rally as investors try to make the most of August’s losses. Traders are neck-deep into a data-heavy week from company fiscal reports that could chart the hike path for interest rates. ...
Jonathon Brown | August 31, 2023 |

A New Frontier in Psychedelic Therapeutics

Cybin X Kernel "A New Frontier in Psychedelic Therapeutics" About the partnership: Cybin Corporation ( N.CYBN , Forum ) will leverage Kernel’s Flow to quantify brain activity during psychedelic experiences in re...
Featured Submission | January 11, 2021 |

Co-Diagnostics Utilizes CoPrimer Platform to Design New Coronavirus Detection Test

Molecular diagnostics company Co-Diagnostics' shares opened more than 144% higher after the firm reported it has designed a test for virus detection of the new coronavirus, 2019-nCoV, using its CoPrimer™ platform. In the wake of widespread news and worldwide concerns ...
Streetwise Reports | January 24, 2020 |

CytoSorbents Shares Trade 20% Higher as FDA Grants CytoSorb EUA for COVID-19

Shares of CytoSorbents traded higher setting a new 52-week intraday high price after the company reported that the FDA granted emergency use authorization for CytoSorb for use in patients with COVID-19. Critical care immunotherapy company CytoSorbents Corp....
Streetwise Reports | April 14, 2020 |

Psyence Group: natural psychedelics for mental health and wellbeing

Our next company works to help people with a focus on natural psychedelics. Psyence Group uses natural psilocybin products to heal psychological trauma and to calm the mind during someone’s last stage of life while in palliative care. Here with us toda...
Brieanna McCutcheon | March 2, 2023 |

BioNTech, CureVac, Valeo Pharma - COVID-19 wakes up the industry

In the past, people have accepted that it usually takes about ten years to get a vaccine on the market. Careful testing with proof of success is required for a preparation to receive approvals. Since COVID-19, the pressure to develop has increased dramatically and also the pot...
Mario Hose | September 1, 2020 |

A ‘Novel’ Investment In Psychedelic-Inspired Medicines

Stockhouse investors are keenly aware of the booming trend in the psychedelic healthcare space…in many ways the new Cannabis 2.0 over the last 12 – 24 months. Capital markets have taken to them en masse – a market now estimated to be in excess of USD$5 billion and expected ...
Dave Jackson | April 16, 2021 |
1 2 3 4